{"id":413449,"date":"2022-05-24T00:00:00","date_gmt":"2022-05-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0019-2022-biopharma-multiple-sclerosis-current-treatment-physician-insights-eu5-2022\/"},"modified":"2026-03-31T10:39:27","modified_gmt":"2026-03-31T10:39:27","slug":"cutrcg0019-2022-biopharma-multiple-sclerosis-current-treatment-physician-insights-eu5-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0019-2022-biopharma-multiple-sclerosis-current-treatment-physician-insights-eu5-2022\/","title":{"rendered":"Multiple Sclerosis | Current Treatment: Physician Insights | EU5 | 2022"},"content":{"rendered":"<p>A handful of newer disease-modifying therapies (DMTs) for multiple sclerosis (MS)\u2014Novartis\u2019s Mayzent, Bristol Myers Squibb\u2019s Zeposia, Novartis\u2019s Kesimpta, and Janssen\u2019s Ponvory\u2014have received EU approval and have launched in the crowded MS market. Given the rapid pace of change in the MS market, developers of both current and emerging DMTs must continually reassess their products\u2019 differentiation and likely positioning in this highly competitive space. This report will explore neurologists\u2019 perceptions of established and newly launched DMTs, their prescribing habits in today\u2019s market, and anticipated changes in brand usage as more DMTs expand\u2014and further complicate\u2014prescriber choice.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>How are different MS subpopulations (i.e., clinically isolated syndrome, relapsing-remitting, active secondary-progressive, nonactive secondary-progressive, and primary-progressive) treated today?<\/li>\n<li>How do product shares differ across lines of therapy? Are high-efficacy therapies factoring more into early-line treatment decisions?<\/li>\n<li>How do EMA label restrictions and country-specific guidelines impact prescribing freedom in the European MS markets? What is the size of the eligible population based on certain labels, according to neurologists?<\/li>\n<li>How has neurologists\u2019 prescribing changed in the past year, and why? What further changes do they expect within the next year?<\/li>\n<li>What are neurologists\u2019 opinions of the newest entrants in the MS market, and how are they incorporating these DMTs in the treatment paradigm?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Current Treatment: Physician Insights <\/em>provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><strong>Markets Covered:<\/strong><strong> <\/strong> <strong> <\/strong>France, Germany, Italy, Spain, and the United Kingdom.<\/p>\n<p><strong>Primary research:<\/strong><strong> <\/strong> Survey of 50 neurologists in France, Germany, Italy, Spain, and the United Kingdom.<\/p>\n<p><strong>Key drugs covered: <\/strong>Aubagio, glatiramer acetate, Gilenya, Interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ponvory, Tecfidera, Tysabri, Zeposia, Vumerity<\/p>\n<p><strong>Key companies: <\/strong>Biogen, Bristol Myers Squibb, Janssen, Merck KGaA, Novartis, Roche, Sanofi Genzyme, Teva, Viatris<\/p>\n<p><strong>Key insights provided:<\/strong><\/p>\n<ul>\n<li>Factors influencing disease management and treatment decisions.<\/li>\n<li>Drivers and constraints of treatment selection.<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares.<\/li>\n<li>Rationale for changes in treatment approach.<\/li>\n<li>Physician insight on persistency and compliance.<\/li>\n<li>Physician-reported recent\/anticipated changes in brand usage or treatment approach.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-413449","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-product-current-treatment","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/413449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/413449\/revisions"}],"predecessor-version":[{"id":413764,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/413449\/revisions\/413764"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=413449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}